No Data
No Data
Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine's Strong Financial Health and Promising Clinical Pipeline Justify Buy Rating
Disc Medicine | 10-Q: Q1 2025 Earnings Report
Disc Medicine Reports Q1 EPS ($1.02), Consensus ($1.07)
Disc Medicine | 8-K: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update